The Man Van Project
A legfontosabb adatok
- Ki végzi
- Royal Marsden NHS Foundation Trust
- Hol
- London (Egyesült Királyság)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 4000 fő, tervezett
- Kezdés
- 2022. ápr. 13.
- Várható befejezés
- 2026. dec. 1.
- A vizsgálat típusa
- Beavatkozással járó, 8 csoport
- A vizsgált kezelések
- MV-POCT Sub-study
- Main Man Van Group Sub-study (MV-Eco)
- MV-QualQ Sub-study
- MV-PRS Sub-study
- MV-DNA and MV-UctDNA Sub-study
- Man Van patients
- MV-SSI Sub-study
- MV-TPP Sub-study
- A regiszteradat frissítve
- 2024. május 1.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat olyan férfiakat keres, akik igénybe veszik a Man Van mobil egészségügyi rendelőt, amely prosztatarákot és más férfirákokat szűr. Egyes részekben egészségügyi dolgozók, betegek és más szakértők is részt vehetnek.
- Életkor
- Fő vizsgálat: 45 éves vagy idősebb. Egyes részvizsgálatok: 18 év felett. A nyilvántartás szerinti legalacsonyabb életkor 18 év.
- Nem
- A fő vizsgálatban csak férfiak vehetnek részt.
- Biomarker vagy leletérték
- Egyes részvizsgálatokban PSA-vizsgálat és/vagy HbA1c-vizsgálat, illetve vér-, nyál- vagy vizeletminta szerepel.
A részvétel fő kizáró okai
- Az a Man Van beteg, aki már részt vett időponton, nem vehet részt az interjús részvizsgálatban (MV-SSI)
- Akik nem akarnak részt venni
- Akik nem értik a szóbeli vagy írásbeli angol nyelvű tájékoztatást (interjús részvizsgálatok)
- Akik nem tudnak írásban és szóban beleegyezni (betegcsoport)
- Nincs közvetlen vagy közvetett tapasztalat prosztata-, hasnyálmirigy- vagy emésztőrendszeri rákkal (betegcsoport)
A regiszter feltételei, szó szerint
Mind a 41 feltétel megnézéseKevesebb
Ki vehet részt
- Participating in the linked Man Van mobile outreach clinic
- Age ≥45 years
- Male; (The initial pilot study had a age criteria of ≥18 years, but this was amended); MV-POCT
- MV-QualQ
- MV-Eco
- MV-PRS
- MV-DNA
- MV MV-UctDNA
- MV-SSI
- Aged > 18 and over (on date of invitation to participate)
- Works for healthcare organisation, other stakeholder or professional or potential man van patient who was not seen or relative of a Man Van patient/potential patient
- Healthcare Professionals
- Aged > 18 and over (on date of invitation to participate)
- Speaks English
- Works within the UK
- Profession: GPs, Practice Staff (Nurses, Physician Assistants and Associates
- Healthcare assistants)
- Experienced in adopting new tests and guidelines into practice
- Experienced in detecting, managing, and referring symptoms and asymptomatic patients with symptoms of prostate, pancreatic, GI cancer and/or are at an increased risk of developing these cancers; Patients
- Aged > 18 and over (on date of invitation to participate)
- Speaks English
- Lives in the UK
- Patients with direct and in-direct experience with prostate, pancreatic, GI cancers
- Patients at an increased risk of developing prostate, pancreatic, GI cancer in accordance with known risk factors, which includes age, smoking, being overweight or obese, family history and genetic factors, pancreatitis, and diabetes; Other key stakeholders/professionals
- Aged > 18 and over (on date of invitation to participate)
- Speak English
- Works within the UK
- Professions: medical devices and biomedical researchers, scientists, representatives for major regulatory and funding bodies
- Knowledgeable of Early Detection initiatives (tests, outreach programes)
Ki nem vehet részt
- Individuals with no experience in adopting new cancer tests and guidelines into practice
- Individuals with no experience in in detecting, managing, and referring patients with symptoms of cancer and/or are at an increased risk of developing prostate, pancreatic, GI cancer
- No direct or indirect lived experience with prostate, pancreatic, GI cancers; Non-clinical key stakeholders/professionals • Individuals who are unwilling to take part in the study • Individuals who are not familiar with cancer biomarkers and medical tests • Individuals with no knowledge of early detection
- Man van patient who has attended appointment; MV-TPP
- GPs
- Individuals who are unwilling to take part in the study
- Individuals who do not adequately understand verbal explanations or written information in English; Patients • Individuals who are unwilling to take part in the study
- Individuals who do not adequately understand verbal explanations or written information in English
- Unable to provide written and verbal consent
- Individuals who do not adequately understand verbal explanations or written information in English
Egyéb feltételek
- Patients are eligible to be included in the research study if they are eligible to access the Man Van mobile outreach clinic, which is a novel clinical service delivered by The Royal Marsden Hospital NHS Foundation Trust. The inclusion and exclusion criteria have been designed to be as broad as possible, in order to include data from as many patients using the Man Van clinical service as possible
- As the primary purpose of the Man Van mobile outreach clinic is to screen for prostate, testicular, penile and other cancers that affect men, only men are eligible to be reviewed in the mobile outreach clinic hence only males will be recruited into this study
Helyszínek itt: Egyesült Királyság
- Royal Marsden Hospital NHS Foundation TrustLondon, Egyesült KirályságContact: Ann GandolfiRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
National Health Service (NHS) England has commissioned The Royal Marsden Hospital NHS Foundation Trust to run a novel mobile clinical outreach service called 'Man Van' with the aim of enabling male patients' easy access to care at the site of their work and in their communities. The initial focus of this new standard of care clinic is to access workplaces with large manual workforces where large scale working from home is not possible. These will include logistics firms and bus companies. These companies employ large numbers of black and minority ethnic men who also have poorer outcomes with a range of other diseases, including Coronavirus disease (COVID)-19. The novel clinical service will collaborate with Unite (and other unions) as well as employers in order to reach our target groups effectively. There is also the opportunity to target higher risk groups e.g. Afro Caribbean communities whose rates of prostate cancer are 1 in 41 as well as occupational higher risk categories. The Man Van has the potential to swing the balance of evidence in favour of Prostate-Specific Antigen (PSA) screening, with a targeted screening program directed at high-risk groups including ethnic minorities and manual workers. Reasons for poorer outcomes amongst these groups are multi-factorial and complex. Levels of education are often a factor which can impact the understanding of the disease and how to seek assistance. Distrust of medical organisations has also been cited as a factor.
A teljes eredeti leírásKevesebb
The aim of the Man Van mobile outreach service is to enable men access to a specific men's health service - focusing on general health and wellbeing (including BMI assessment, blood pressure, blood sugar/diabetes checks etc) and a prostate check for those who raise concerns. This will include a PSA test where relevant. This will be the core data gathered from the project.
Patients will receive PSA results in the 'Man Van' by a clinical nurse specialist with patients with raised PSA levels being referred into the standard rapid referral cancer pathways. Similar considerations will apply to men with haematuria detected on dip stick testing or who present with a testicular mass or penile lesion (both rare but important).
The clinical data generated from each routine health screening appointment will be analysed to determine the effectiveness of the Man Van mobile outreach model in identifying prostate and other male cancers and other co-morbidities much earlier than if patients had waited to present to their General Practitioner (GP) or other healthcare provider.
Patients who receive an early diagnosis of clinically significant prostate cancer will have access to early curative treatments, which are typically less invasive and shorter in timescales. Similar interventions have shown large scale success in particular with breast and cervical cancer.
The NHS sees many patients accessing cancer care at a late stage. Reducing this trend is a key objective of the NHS Long Term Plan. The COVID-19 pandemic has further exacerbated health inequalities and mobile clinics can potentially be a model for alleviating this. To enable patients access to medical treatment earlier there is a need to make the 'seeking advice on men's health and prostate issues' less daunting, more normal and easily accessible. The 'Man Van' has the ability to do just that and it is anticipated that the findings of this research, using the data generated from each patient's routine health screening, will demonstrate that a mobile outreach model is more effective in identifying cancers at an earlier stage than 'traditional' diagnostic pathways.
We also hope to evaluate the Man Van with a qualitative study looking at the patient perspectives from those who utilise the Man Van.
The reasons for high risk in prostate cancer are heavily linked to genetics. This is an issue as there is less recruitment of high risk groups to studies. We hope to gather genetic data from a higher proportion of genetically susceptible men via the Man Van, which can be used in future to further genetic knowledge of prostate cancer.
A vizsgálat 8 csoportja
- Main Group (MV-Eco) Sub-studyEgyéb csoport
Patients seen in the Man Van, including those consenting to long-term follow-up of data.
Kezelés: Main Man Van Group Sub-study (MV-Eco) és Man Van patients
- Point of care testing (MV-POCT) Sub-studyEgyéb csoport
Patients consenting to a point of care blood test for either a PSA and/or HbA1c
Kezelés: MV-POCT Sub-study és Man Van patients
- Qualitative questionnaire (MV-QualQ) Sub-studyEgyéb csoport
Patients consenting to participate in a qualitative study about their experience of the Man Van.
Kezelés: MV-QualQ Sub-study és Man Van patients
- Polygenic risk scores (MV-PRS) Sub-studyEgyéb csoport
Patients consenting for a polygenic risk score test.
Kezelés: MV-PRS Sub-study és Man Van patients
- DNA Collection (MV-DNA) and Urinary Circulating Tumour DNA collection (MV-UctDNA) Sub-studiesEgyéb csoport
Patients consenting to collection of DNA and/or urine for as yet undetermined future ethically-approved research.
Kezelés: MV-DNA and MV-UctDNA Sub-study és Man Van patients
- Man Van patientsEgyéb csoport
All patients seen within Man Van
- Stakeholder service interviews (MV-SSI) Sub-StudyEgyéb csoport
Semi-structured interviews with people involved in the running of the project or those who may help in recruiting patients. This may include but not be limited to: GPs, community leaders (e.g. church pastors), charity leaders, staff involved in delivery (nurses, co-ordinators), men who did not attend the service and relatives of men.
Kezelés: MV-SSI Sub-study
- Target product profile (MV-TPP) Sub-StudyEgyéb csoport
We will develop an equity-focused Target Product Profile (TPP) that can provide a summary of the requirements for an optimal yet realistic profile of biomarker tests designed to work in mobile testing clinics, such as the Man Van.
Kezelés: Man Van patients és MV-TPP Sub-study
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- The Man Van Project: An Evaluation of the Effectiveness of a Mobile Outreach Screening Clinic Model for Earlier Detection of Prostate Cancer and Other Male Cancers
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
- A regiszteradat frissítve
- 2024. május 1.